Research progress on the mechanism of glycolysis in ovarian cancer

被引：12
作者：
Li, Chan [1 ]
Liu, Fang-Yuan [1 ]
Shen, Ying [1 ,2 ]
Tian, Yuan [3 ]
Han, Feng-Juan [2 ]
机构：
[1] Heilongjiang Univ Tradit Chinese Med TCM, Harbin, Heilongjiang, Peoples R China
[2] Heilongjiang Univ Tradit Chinese Med TCM, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[3] Zhejiang Univ Chinese Med, Hangzhou, Zhejiang, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金：
中国国家自然科学基金;
关键词：
ovarian cancer; glycolysis; hexokinase; phosphofructokinase; pyruvate kinase; CELL-PROLIFERATION; AEROBIC GLYCOLYSIS; METABOLISM; ACID; CHEMOTHERAPY; FIBROBLASTS; RESISTANCE; GROWTH; MYC;
D O I：
10.3389/fimmu.2023.1284853
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Glycolysis is the preferred energy metabolism pathway in cancer cells even when the oxygen content is sufficient. Through glycolysis, cancer cells convert glucose into pyruvic acid and then lactate to rapidly produce energy and promote cancer progression. Changes in glycolysis activity play a crucial role in the biosynthesis and energy requirements of cancer cells needed to maintain growth and metastasis. This review focuses on ovarian cancer and the significance of key rate-limiting enzymes (hexokinase, phosphofructokinase, and pyruvate kinase, related signaling pathways (PI3K-AKT, Wnt, MAPK, AMPK), transcription regulators (HIF-1a), and non-coding RNA in the glycolytic pathway. Understanding the relationship between glycolysis and these different mechanisms may provide new opportunities for the future treatment of ovarian cancer.
引用
收藏
页数：12
相关论文
共 92 条
  • [1] MicroRNA-mediated regulation of glucose and lipid metabolism
    Agbu, Pamela
    Carthew, Richard W.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2021, 22 (06) : 425 - 438
  • [2] Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism
    Ai, Zhihong
    Lu, Yang
    Qiu, Songbo
    Fan, Zhen
    [J]. CANCER LETTERS, 2016, 373 (01) : 36 - 44
  • [3] SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer
    Bandopadhyay, Shreya
    Prasad, Parash
    Ray, Upasana
    Ghosh, Damayanti Das
    Roy, Sib Sankar
    [J]. FEBS OPEN BIO, 2022, 12 (09): : 1657 - 1676
  • [4] The potential utility of PFKFB3 as a therapeutic target
    Bartrons, Ramon
    Rodriguez-Garcia, Ana
    Simon-Molas, Helga
    Castano, Esther
    Manzano, Anna
    Navarro-Sabate, Aurea
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (08) : 659 - 674
  • [5] NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells
    Bernacchioni, Caterina
    Ghini, Veronica
    Cencetti, Francesca
    Japtok, Lukasz
    Donati, Chiara
    Bruni, Paola
    Turano, Paola
    [J]. MOLECULAR ONCOLOGY, 2017, 11 (05) : 517 - 533
  • [6] Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment
    Bi, Jianlei
    Bi, Fangfang
    Pan, Xue
    Yang, Qing
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [7] MICU1 drives glycolysis and chemoresistance in ovarian cancer
    Chakraborty, Prabir K.
    Mustafi, Soumyajit Banerjee
    Xiong, Xunhao
    Dwivedi, Shailendra Kumar Dhar
    Nesin, Vasyl
    Saha, Sounik
    Zhang, Min
    Dhanasekaran, Danny
    Jayaraman, Muralidharan
    Mannel, Robert
    Moore, Kathleen
    McMeekin, Scott
    Yang, Da
    Zuna, Rosemary
    Ding, Kai
    Tsiokas, Leonidas
    Bhattacharya, Resham
    Mukherjee, Priyabrata
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [8] Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer
    Chao, Tai-Kuang
    Huang, Tien-Shuo
    Liao, Yu-Ping
    Huang, Rui-Lan
    Su, Po-Hsuan
    Shen, Hueng-Yuan
    Lai, Hung-Cheng
    Wang, Yu-Chi
    [J]. PLOS ONE, 2017, 12 (07):
  • [9] TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer
    Chen, Min
    Sheng, Xiu-Jie
    Qin, Yuan-Yi
    Zhu, Song
    Wu, Qing-Xia
    Jia, Liqing
    Meng, Nan
    He, Yu-Tian
    Yan, Guang-Rong
    [J]. THERANOSTICS, 2019, 9 (03): : 676 - 690
  • [10] TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation
    Chen, Yongchang
    Liu, Lu
    Xia, Longzheng
    Wu, Nayiyuan
    Wang, Ying
    Li, He
    Chen, Xue
    Zhang, Xiaoye
    Liu, Zhaoyi
    Zhu, Miaochen
    Liao, Qianjin
    Wang, Jing
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
12345678910